Skip to main content
Clinical Trials/CTRI/2023/07/055462
CTRI/2023/07/055462RecruitingNot Applicable

An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients

Pfizer Ltd4 sites in 1 country3,000 target enrollmentStarted: July 31, 2023Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Pfizer Ltd
Enrollment
3,000
Locations
4
Primary Endpoint
to evaluate the epidemiological burden of mild, moderate and severe AD,vitiligo,and AA across enrolled dermatology centers

Study Overview

Brief Summary

The objective of this registry is to evaluate the epidemiological burden of mild, moderate and severe AD, vitiligo, and AA across enrolled dermatology centers.

Elucidate the current diagnostic criteria and grading modalities for AD, vitiligo, and AA in India.

There is no study-related intervention.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
2.00 Year(s) to 64.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Be aged between 2 and 64 years old.
  • Clinical diagnosis of Vitiligo, AA or AD.
  • Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria

  • Patients meeting any of the following criteria will not be included in the study:
  • Not willing to provide written informed consent.
  • Not willing for a follow-up visit.

Outcomes

Primary Outcomes

to evaluate the epidemiological burden of mild, moderate and severe AD,vitiligo,and AA across enrolled dermatology centers

Time Frame: followup visits take place at intervals at the investigators discretion.

Secondary Outcomes

  • To elucidate the current diagnostic criteria and grading modalities for AD,vitiligo,and AA in India.(followup visits take place at intervals at the investigators discretion.)

Investigators

Sponsor
Pfizer Ltd
Sponsor Class
Pharmaceutical industry-Global

Study Sites (4)

Loading locations...

Similar Trials